Titre : | Restrictions on access to direct-acting antivirals for people who inject drugs: The European Hep-CORE study and the role of patient groups in monitoring national HCV responses [Viewpoint] (2017) |
Auteurs : | J. V. LAZARUS ; K. SAFREED-HARMON ; S. R. STUMO ; M. JAUFFRET-ROUSTIDE ; M. MATICIC ; T. REIC ; E. SCHATZ ; J. TALLADA ; M. HARRIS ; HEP-CORE STUDY GROUP |
Type de document : | Article : Périodique |
Dans : | International Journal of Drug Policy (Vol.47, September 2017) |
Article en page(s) : | 47-50 |
Langues: | Anglais |
Discipline : | MAL (Maladies infectieuses / Infectious diseases) |
Mots-clés : |
Thésaurus mots-clés ACCES AUX SOINS ; HEPATITE ; ANTIVIRAUX ; INJECTION ; USAGERThésaurus géographique EUROPE |
Résumé : | In 2016, the World Health Organization (WHO) called for the elimination of viral hepatitis as a public health threat and established the ambitious targets of achieving an 80% reduction in new infections and a 65% reduction in deaths from hepatitis C virus (HCV) by 2030 (WHO, 2016a). The sharing of unsterile injecting equipment is a major driver of the European region's HCV epidemic (Hope, Eramova, Capurro, & Donoghoe, 2014; ECDC, 2015), and European countries are unlikely to reach the WHO targets unless they squarely address the HCV prevention, testing and treatment needs of people who inject drugs (PWID). [Extract] |
Domaine : | Drogues illicites / Illicit drugs |
Affiliation : | CHIP, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark |
Cote : | Abonnement |
Accueil